PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy

4-1BB has been considered a promising target in cancer immunotherapy for decades. Nevertheless, early 4-1BB-targeted agents demonstrated significant liver immuno-toxicity. A new wave of 4-1BB-based therapy is being developed to circumvent hepatotoxicity with a bispecific molecule that directs 4-1BB agonism to the tumor microenvironment by targeting tumor-associated immune checkpoint molecule PD-L1.

Automated summary

4-1BB has long been considered a promising target for cancer immunotherapy, but early targeted agents showed significant liver toxicity. A new approach is being developed to circumvent hepatotoxicity by directing 4-1BB agonism to the tumor microenvironment using a bispecific molecule targeting the tumor-associated immune checkpoint molecule PD-L1.